4-HYDROXYWARFARIN
4-HYDROXYWARFARIN structure
|
Common Name | 4-HYDROXYWARFARIN | ||
|---|---|---|---|---|
| CAS Number | 24579-14-4 | Molecular Weight | 324.32700 | |
| Density | 1.384g/cm3 | Boiling Point | 522ºC at 760mmHg | |
| Molecular Formula | C19H16O5 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 190.3ºC | |
| Symbol |
GHS05, GHS07 |
Signal Word | Danger | |
| Name | 4-hydroxy-3-[1-(4-hydroxyphenyl)-3-oxobutyl]chromen-2-one |
|---|---|
| Synonym | More Synonyms |
| Density | 1.384g/cm3 |
|---|---|
| Boiling Point | 522ºC at 760mmHg |
| Molecular Formula | C19H16O5 |
| Molecular Weight | 324.32700 |
| Flash Point | 190.3ºC |
| Exact Mass | 324.10000 |
| PSA | 87.74000 |
| LogP | 3.31520 |
| Vapour Pressure | 1E-11mmHg at 25°C |
| Index of Refraction | 1.658 |
| Symbol |
GHS05, GHS07 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H302-H318 |
| Precautionary Statements | P280-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | 22-41 |
| Safety Phrases | 26-39 |
| RIDADR | NONH for all modes of transport |
| HS Code | 2914501900 |
|
~%
4-HYDROXYWARFARIN CAS#:24579-14-4 |
| Literature: Journal of Pharmacy and Pharmacology, , vol. 39, # 2 p. 142 - 144 |
|
~%
4-HYDROXYWARFARIN CAS#:24579-14-4 |
| Literature: Rizzo; Davis Journal of Pharmaceutical Sciences, 1989 , vol. 78, # 3 p. 183 - 189 |
|
~%
4-HYDROXYWARFARIN CAS#:24579-14-4 |
| Literature: Rizzo; Davis Journal of Pharmaceutical Sciences, 1989 , vol. 78, # 3 p. 183 - 189 |
| HS Code | 2914501900 |
|---|---|
| Summary | 2914501900 other ketone-phenols。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:5.5%。General tariff:30.0% |
|
Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
Chem. Res. Toxicol. 23(5) , 939-45, (2010) Coumadin (R/S-warfarin) anticoagulant therapy poses a risk to over 50 million Americans, in part due to interpersonal variation in drug metabolism. Consequently, it is important to understand how meta... |
|
|
Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.
Drug Metab. Lett. 6(3) , 157-64, (2012) Coumadin (R/S-warfarin) is a highly efficacious and widely used anticoagulant; however, its highly variable metabolism remains an important contributor to uncertainties in therapeutic responses. Pharm... |
|
|
Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.
Drug Metab. Lett. 4(4) , 213-9, (2010) Effective coumadin (R/S-warfarin) therapy is complicated by inter-individual variability in metabolism. Recent studies have demonstrated that CYP3A isoforms likely contribute to patient responses and ... |
| 4-Hydroxywarfarin |
| 4'-Hydroxywarfarin |